NancySarahShulmanMD

Infectious Disease • San Mateo, CA

HIV/AIDS Medicine

Attending Physician

Join to view full profile

Dr. Shulman is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Shulman's full profile

Already have an account?

Office
Edison Clinic
222 W. 39th Ave
San Mateo, CA 94403

Education & Training

Stanford Health Care-Sponsored Stanford UniversityFellowship, Infectious Disease, 1996 - 2000
University of ChicagoResidency, Internal Medicine, 1991 - 1995
University of Kansas School of MedicineClass of 1991

Certifications & Licensure

CA State Medical License 1995 - 2025
IL State Medical License 1991 - 1996

Clinical Trials

Maraviroc as an Immunomodulatory Drug for Antiretroviral-treated HIV Infected Patients Exhibiting Immunologic Failure Start of enrollment: 2008 Sep 01
Completed
Phase 4

Publications & Presentations

PubMed

15 citations
Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir in Patients With Hepatitis C Virus Genotype 1 or 4 Infection and Advanced Kidney Disease.
Eric Lawitz, Edward Gane, Eric Cohen, John M. Vierling, Kosh Agarwal
Kidney International Reports. 2019-02-01
20 citations
Dynamic changes in innate immune responses during direct-acting antiviral therapy for HCV infection.
Jacinta A. Holmes, Charles Carlton-Smith, Arthur Y. Kim, Emily O. Dumas, Joelle Brown
Journal of Viral Hepatitis. 2019-01-03
2 citations
Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir ± Ribavirin for HCV in Brazilian Adults with Advanced Fibrosis.
Mario G. Pessoa, Jose Valdez Ramalho-Madruga, Katia Alves, Estevão P. Nunes, Hugo Cheinquer
Annals of Hepatology. 2018-10-16

Journal Articles

inform \
shulman, lancet

Press Mentions

Bluejay Therapeutics Advances in Hepatitis B and D Trials: Successfully Completes BJT-778 Phase 1a Study and Begins Phase 1b Trial EnrollmentJune 3rd, 2023

Grant Support

Feasibility Of CCR5 Inhibitors In Preventing Maternal To Infant SIV TransmissionNational Center For Research Resources2009–2010
Feasibility Of CCR5 Inhibitors In Preventing Maternal To Infant SIV TransmissionNational Institute Of Allergy And Infectious Diseases2008–2009
Non-Nucleoside Reverse Transcriptive HypersensitivityNational Institute Of Allergy And Infectious Diseases2002–2006